JP2020114837A5 - - Google Patents

Download PDF

Info

Publication number
JP2020114837A5
JP2020114837A5 JP2020049116A JP2020049116A JP2020114837A5 JP 2020114837 A5 JP2020114837 A5 JP 2020114837A5 JP 2020049116 A JP2020049116 A JP 2020049116A JP 2020049116 A JP2020049116 A JP 2020049116A JP 2020114837 A5 JP2020114837 A5 JP 2020114837A5
Authority
JP
Japan
Prior art keywords
approximately
administered
cell immunotherapy
dose
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020049116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020114837A (ja
JP7162632B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020114837A publication Critical patent/JP2020114837A/ja
Publication of JP2020114837A5 publication Critical patent/JP2020114837A5/ja
Application granted granted Critical
Publication of JP7162632B2 publication Critical patent/JP7162632B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020049116A 2017-04-01 2020-03-19 細胞免疫療法前の細胞毒性プレコンディショニングの代替 Active JP7162632B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762480414P 2017-04-01 2017-04-01
US62/480,414 2017-04-01
US201862613697P 2018-01-04 2018-01-04
US62/613,697 2018-01-04
US201862624454P 2018-01-31 2018-01-31
US62/624,454 2018-01-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018551293A Division JP6748221B2 (ja) 2017-04-01 2018-03-30 細胞免疫療法前の細胞毒性プレコンディショニングの代替

Publications (3)

Publication Number Publication Date
JP2020114837A JP2020114837A (ja) 2020-07-30
JP2020114837A5 true JP2020114837A5 (cg-RX-API-DMAC7.html) 2021-05-06
JP7162632B2 JP7162632B2 (ja) 2022-10-28

Family

ID=62111173

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018551293A Active JP6748221B2 (ja) 2017-04-01 2018-03-30 細胞免疫療法前の細胞毒性プレコンディショニングの代替
JP2020049116A Active JP7162632B2 (ja) 2017-04-01 2020-03-19 細胞免疫療法前の細胞毒性プレコンディショニングの代替

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018551293A Active JP6748221B2 (ja) 2017-04-01 2018-03-30 細胞免疫療法前の細胞毒性プレコンディショニングの代替

Country Status (13)

Country Link
US (2) US11219628B2 (cg-RX-API-DMAC7.html)
EP (1) EP3490605B1 (cg-RX-API-DMAC7.html)
JP (2) JP6748221B2 (cg-RX-API-DMAC7.html)
KR (1) KR102509006B1 (cg-RX-API-DMAC7.html)
CN (1) CN110475571B (cg-RX-API-DMAC7.html)
AU (1) AU2018243753A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019020214A2 (cg-RX-API-DMAC7.html)
CA (1) CA3054443A1 (cg-RX-API-DMAC7.html)
ES (1) ES2954311T3 (cg-RX-API-DMAC7.html)
IL (1) IL269209B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019011679A (cg-RX-API-DMAC7.html)
SG (1) SG11201907744QA (cg-RX-API-DMAC7.html)
WO (1) WO2018183927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2025019711A2 (en) * 2023-07-19 2025-01-23 Dermtech, Inc. Predicting therapeutic response based on biomarker signatures
BR112019020214A2 (pt) 2017-04-01 2020-04-22 Avm Biotechnology Llc substituição do pré-condicionamento citotóxico antes da imunoterapia celular
CA3066361A1 (en) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Intravascular fluid movement devices, systems, and methods of use
EP3710076B1 (en) 2017-11-13 2023-12-27 Shifamed Holdings, LLC Intravascular fluid movement devices, systems, and methods of use
CN112004563B (zh) 2018-02-01 2024-08-06 施菲姆德控股有限责任公司 血管内血泵以及使用和制造方法
WO2019204462A2 (en) 2018-04-17 2019-10-24 Celldex Therapeutics, Inc. Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US12161857B2 (en) 2018-07-31 2024-12-10 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
WO2020073047A1 (en) 2018-10-05 2020-04-09 Shifamed Holdings, Llc Intravascular blood pumps and methods of use
BR112021009365A2 (pt) * 2018-11-14 2021-08-10 Avm Biotechnology, Llc formulação de glicocorticoide estável
EP3880216B1 (en) * 2018-11-16 2025-04-09 Rapa Therapeutics, LLC Methods for treating cancer with manufactured t cells
WO2020123444A1 (en) * 2018-12-11 2020-06-18 Celldex Therapeutics, Inc. Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
JP2022540616A (ja) 2019-07-12 2022-09-16 シファメド・ホールディングス・エルエルシー 血管内血液ポンプならびに製造および使用の方法
WO2021016372A1 (en) 2019-07-22 2021-01-28 Shifamed Holdings, Llc Intravascular blood pumps with struts and methods of use and manufacture
US12465748B2 (en) 2019-08-07 2025-11-11 Supira Medical, Inc. Catheter blood pumps and collapsible pump housings
WO2021062260A1 (en) 2019-09-25 2021-04-01 Shifamed Holdings, Llc Catheter blood pumps and collapsible blood conduits
EP4034192B1 (en) 2019-09-25 2025-12-24 Supira Medical, Inc. Intravascular blood pump systems and methods of use and control thereof
EP4501393A3 (en) 2019-09-25 2025-04-09 Shifamed Holdings, LLC Catheter blood pumps and collapsible pump housings
IL292665B1 (en) * 2019-11-06 2025-10-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
EP4072650A4 (en) 2019-12-11 2024-01-10 Shifamed Holdings, LLC Descending aorta and vena cava blood pumps
CN113189340A (zh) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 细胞焦亡通路在细胞治疗中的用途
US12252701B2 (en) 2020-02-20 2025-03-18 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
BR112022016803A2 (pt) 2020-02-28 2022-11-08 Avm Biotechnology Llc População de linfócitos e métodos para produzir os mesmos
CN111443210B (zh) * 2020-04-10 2023-09-22 青海大学附属医院 泡型包虫病早期诊疗生物标志物及其应用
CN115989038A (zh) * 2020-04-10 2023-04-18 北卡罗莱纳州立大学 使用材料支架的增强的哺乳动物细胞病毒转导
BR112022021691A2 (pt) 2020-04-29 2022-12-20 Avm Biotechnology Llc Moduladores de receptor de glicocorticoide (gr) para tratar um vírus sars-cov-2
KR20230018422A (ko) 2020-06-01 2023-02-07 에이브이엠 바이오테크놀로지, 엘엘씨 Icam-조절제를 이용한 치료 방법
CN113797313A (zh) * 2020-06-11 2021-12-17 华北制药集团新药研究开发有限责任公司 卡非佐米作为冠状病毒广谱抑制剂的新用途
EP4208538A4 (en) * 2020-09-01 2023-11-08 The National Institute for Biotechnology in the Negev Ltd. Immune system restoration by cell therapy
CN113322233A (zh) * 2021-04-19 2021-08-31 格源致善(上海)生物科技有限公司 一种改进的基于新生抗原反应性t细胞的制备方法及应用
EP4326286A4 (en) * 2021-04-23 2025-03-12 Myeloid Therapeutics, Inc. COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY
CN116063401B (zh) * 2021-08-13 2023-12-01 中国人民解放军总医院 阻断型靶向pd-l1的超高亲和力小蛋白及用途
JP2024533093A (ja) 2021-09-01 2024-09-12 エーブイエム・バイオテクノロジー・エルエルシー リンパ球集団およびその産生方法
CN114031678A (zh) * 2021-12-08 2022-02-11 中国科学院新疆理化技术研究所 一种条斑钳蝎毒素多肽组分的制备方法及其应用
CN114767828A (zh) * 2022-04-25 2022-07-22 中国人民解放军海军军医大学 伊沙佐米在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
CN116606352B (zh) * 2023-07-14 2023-09-29 诺赛联合(北京)生物医学科技有限公司 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用
KR20250139235A (ko) 2025-07-15 2025-09-23 김종구 V-aemi 기반 인공지능 감정 음악 창작 시스템 및 그 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
GB9323199D0 (en) 1993-11-10 1994-01-05 Falkenberg J H F Leukaemia treatment
DE69739210D1 (de) 1997-12-16 2009-02-26 Univ Zuerich Diagnostik für übertragbare spongiforme Enzephalopathie
US6406699B1 (en) 1999-10-05 2002-06-18 Gary W. Wood Composition and method of cancer antigen immunotherapy
US20030099621A1 (en) * 2001-11-29 2003-05-29 Robert Chow Stem cell screening and transplantation therapy for HIV infection
IL146970A0 (en) 2001-12-06 2002-08-14 Yeda Res & Dev Migration of haematopoietic stem cells and progenitor cells to the liver
EP1499347A2 (en) 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
KR100822149B1 (ko) 2002-05-17 2008-04-15 셀진 코포레이션 암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물
GB0310593D0 (en) 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
US20040247574A1 (en) 2003-05-27 2004-12-09 Christopherson Kent W. Methods for enhancing stem cell engraftment during transplantation
WO2006071778A2 (en) 2004-12-23 2006-07-06 Ethicon Incorporated Treatment of parkinson's disease and related disorders using postpartum derived cells
PL1874821T3 (pl) * 2005-04-26 2013-09-30 Trion Pharma Gmbh Kombinacja przeciwciał i glikokortykoidów do leczenia raka
RU2486204C2 (ru) 2005-07-22 2013-06-27 Уай'З Терапьютикс Ко., Лтд. Антитела против сd26 и способы их применения
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
GB0700058D0 (en) 2007-01-03 2007-02-07 Scancell Aps Anti-tumor vaccine based on normal cells
CA2677214A1 (en) 2007-02-01 2008-08-07 Nephrogen, Llc Potentiation of stem cell homing and treatment of organ dysfunction or organ failure
EP2288387B1 (en) * 2008-05-23 2013-02-13 Argos Therapeutics, Inc. Novel soluble cd83 polypeptides, formulations and methods of use
US20090299269A1 (en) 2008-05-29 2009-12-03 John Foley Vascular stimulation to aid intravascular cell replacement therapy
WO2009152186A1 (en) 2008-06-09 2009-12-17 American Stem Cell, Inc. Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors
ES2627043T3 (es) 2008-06-09 2017-07-26 Targazyme, Inc. Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa
US20100055107A1 (en) * 2008-07-31 2010-03-04 Defu Zeng Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning
US10426740B1 (en) * 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
WO2012024519A2 (en) * 2010-08-18 2012-02-23 Theresa Deisher Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
JP2014509841A (ja) 2011-01-18 2014-04-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 癌を治療するための組成物および方法
EP2532740A1 (en) 2011-06-11 2012-12-12 Michael Schmück Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
US10421960B2 (en) 2011-09-16 2019-09-24 The Trustees Of The University Of Pennsylvania RNA engineered T cells for the treatment of cancer
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
PL3888674T3 (pl) * 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
US20180002427A1 (en) * 2015-01-26 2018-01-04 Cellectis Cll1-specific multi-chain chimeric antigen receptor
IL312426B1 (en) 2015-05-28 2025-10-01 Kite Pharma Inc Methods for training patients for T-cell therapy
EP3548047A4 (en) * 2016-11-30 2020-07-01 Intrexon Corporation ADMINISTRATION OF STEROIDS AND IMMUNOTHERAPY
BR112019020214A2 (pt) 2017-04-01 2020-04-22 Avm Biotechnology Llc substituição do pré-condicionamento citotóxico antes da imunoterapia celular
EP3488851A1 (en) * 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies

Similar Documents

Publication Publication Date Title
JP2020114837A5 (cg-RX-API-DMAC7.html)
JP2019515888A5 (cg-RX-API-DMAC7.html)
Takada et al. Cyclophosphamide for the treatment of systemic lupus erythematosus
Martin Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis
TW201617093A (zh) 對抗pd-1及pd-l1之拮抗劑與輻射療法組合之治療方法
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
CN113164497A (zh) 免疫消融疗法
JPWO2020261093A5 (cg-RX-API-DMAC7.html)
JP7389486B2 (ja) 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤
Gonsette Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity
US20210380695A1 (en) Sting agonist combination treatments with immune checkpoint inhibitors
Pitarokoili et al. Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis
US6894038B2 (en) Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases
Johnke et al. Response of T lymphocyte populations in prostate cancer patients undergoing radiotherapy: influence of neoajuvant total androgen suppression
Cree et al. Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success
Golfier et al. Antibody therapy maintenance in follicular lymphoma
JP6906154B2 (ja) 造血幹細胞移植患者の処置
JP2023500045A (ja) Stingアゴニストを用いたがんを処置する方法
JP2004523518A (ja) より効能が大きく副作用の少ない癌治療方法
US20200299399A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
CN112773802B (zh) 一种化合物用于预防或治疗移植物抗宿主病的用途
Preparative Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies
Howard Nonsteroidal immunosuppressive therapy for myasthenia gravis
Bordonaro et al. Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: a case report
TW202320788A (zh) 用於治療或預防抗宿主病的吡咯并六元雜芳物